Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma

Tomi Jun, MD
Published: Wednesday, May 31, 2017



Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).

Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.

Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.
 


Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).

Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.

Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x